跳至主要内容
临床试验/NCT06071546
NCT06071546已完成不适用

Pre-market Monocentric Cross-sectional Clinical Investigation of MAIA on Healthy Subjects and Patients With Retinal Pathology: Agreement With MAIA 2013 EDITION Microperimeter and Repeatability Evaluation

Centervue SpA2 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2023年10月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Centervue SpA
入组人数
68
试验地点
2
主要终点
To evaluate the limits of agreement between MAIA and MAIA 2013 EDITION for threshold sensitivity values.

研究概览

简要总结

The purpose of this pre-market, monocentric cross-sectional study is to evaluate the clinical usefulness of a new version of the MAIA device (MAIA) through an agreement with the established version of the MAIA microperimeter (MAIA 2013 EDITION). Moreover, the study aims to evaluate MAIA test-retest repeatability in comparison with MAIA 2013 EDITION and to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects and patients with retinal pathology. All participants will undergo repeated microperimetric examinations with both devices during one single visit.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18-90 years old;
  • BCVA ≥ 0.8 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • IOP ≤ 21 mmHg;
  • Clinically normal appearance of the optic nerve head (examined with Spectralis OCT);
  • Clinically normal appearance of the macula (examined with Spectralis OCT);
  • No ocular pathologies, trauma, surgeries;
  • Absence of pathologies that can affect visual field;
  • No use of drugs inferfering with the correct execution of perimetry;

排除标准

  • Glaucoma or glaucoma suspect diagnosis;
  • IOP ≥ 22 mmHg;
  • Presence or history of disc hemorrhage;
  • Presence of amblyopia;
  • Nystagmus or poor fixation;
  • Previous laser or any ocular surgery, including uncomplicated cataract surgery performed within 6 months before enrollment;
  • Any active infection of anterior or posterior segments;
  • Subjects with significant ocular media opacities;
  • Evidence of diabetic retinopathy, diabetic macular edema, or other retinal disease;
  • Use of any drug that can interfere with the correct execution of microperimetry or that would produce visual field loss;
  • Unable to tolerate ophthalmic imaging;
  • Claustrophobia;
  • Inability to provide informed consent.
  • Patients with retinal pathology
  • Inclusion Criteria:
  • Age: 18-90 years old;
  • BCVA ≥ 0.1 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • Diagnosis of any type of retinal disease by investigator based on fundoscopy and Spectralis OCT for which microperimetry is indicated;
  • Exclusion Criteria:
  • Any ocular surgery, with the exception of uncomplicated cataract surgery performed at least 6 months before enrollment;
  • Subjects unable to tolerate ophthalmic imaging;
  • Nystagmus;
  • Subjects with significant ocular media opacities;
  • Use of any drug that can interfere with the correct execution of microperimetry or that would produce visual field loss;
  • Claustrophobia;
  • Inability to provide informed consent;
  • Vulnerable subjects according to the investigator's judgement.

结局指标

主要结局

To evaluate the limits of agreement between MAIA and MAIA 2013 EDITION for threshold sensitivity values.

时间窗: 1 day

Agreement will be quantified by using the method proposed by Bland and Altman \[1,2,3\], estimating the 95%-Limits of Agreement (LoA) of the difference of threshold sensitivity values. The acceptance criteria for agreement between MAIA and MAIA 2013 EDITION is that MAIA's 95% LoA limits are within MAIA 2013 EDITION repeatability limits. 1. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307-10. 2. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Statistical Methods in Medical Research 8:135-160 3. Bland JM, Altman DG (2007), Agreement Between Methods of Measurement with Multiple Observations Per Individual, Journal of Biopharmaceutical Statistics 17:571-82

次要结局

  • To assess the repeatability limits of retinal threshold sensitivity values obtained with MAIA(1 day)
  • To assess the avoidance of Serious Adverse Device Effects with MAIA(through study completion (expected duration: 3 months))

研究者

发起方
Centervue SpA
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验